Sino Biopharmaceut (SBMFF) Rating Lowered to Hold at Zacks Investment Research

Sino Biopharmaceut (OTCMKTS:SBMFF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “

Sino Biopharmaceut (SBMFF) opened at $1.88 on Wednesday. Sino Biopharmaceut has a twelve month low of $0.72 and a twelve month high of $1.93.

COPYRIGHT VIOLATION WARNING: “Sino Biopharmaceut (SBMFF) Rating Lowered to Hold at Zacks Investment Research” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at

Sino Biopharmaceut Company Profile

Sino Biopharmaceutical Limited, researches, develops, manufactures, and markets Chinese medicines and chemical medicines in Hong Kong. The company operates through three segments: Modernized Chinese Medicines and Chemical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections, Runzhong dispersible tablets, Mingzheng capsules, Tianqingganping enteric capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Yilunping and Tuotuo tablets, as well as Tianqingning injections; and oncology medicines consisting of Zhiruo, Saiweijian, and Tianqingyitai injections.

Receive News & Ratings for Sino Biopharmaceut Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceut and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply